CASI Pharmaceuticals, Inc.

How big is CASI Pharmaceuticals, Inc.?

As of Jun 18, CASI Pharmaceuticals, Inc. has a market capitalization of 23.38 million and reported net sales of 31.37 million, with a net profit loss of 40.47 million. Shareholder's funds were 1.85 million, and total assets were 53.67 million.

As of Jun 18, CASI Pharmaceuticals, Inc. has a market capitalization of 23.38 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 31.37 million for the latest four quarters. However, it also experienced a net profit loss of 40.47 million during the same period.<BR><BR>As of Dec 24, the reporting period shows that shareholder's funds amounted to 1.85 million, while total assets were recorded at 53.67 million.

What does CASI Pharmaceuticals, Inc. do?

CASI Pharmaceuticals, Inc. is a micro-cap biopharmaceutical company focused on developing and commercializing cancer therapeutics. As of March 2025, it reported net sales of $6 million and a net loss of $11 million, with a market cap of $23.38 million.

Overview:<BR>CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of therapeutics for cancer and other medical needs, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 6 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 23.38 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.72 <BR>Return on Equity: 521.41% <BR>Price to Book: -2.90<BR><BR>Contact Details:<BR>Address: 9620 Medical Center Dr Ste 300, ROCKVILLE MD: 20850-3396 <BR>Tel: 1 240 8642600 <BR>Fax: 1 302 6555049 <BR>Website: http://www.casipharmaceuticals.com/

Should I buy, sell or hold CASI Pharmaceuticals, Inc.?

Who are in the management team of CASI Pharmaceuticals, Inc.?

As of March 2022, the management team of CASI Pharmaceuticals, Inc. includes Dr. Wei-Wu He as Executive Chairman and CEO, along with independent directors Mr. James Huang, Mr. Franklin Salisbury, Dr. Rajesh Shrotriya, Dr. Y. Alexander Wu, and Mr. Quan Zhou.

As of March 2022, the management team of CASI Pharmaceuticals, Inc. includes Dr. Wei-Wu He, who serves as the Executive Chairman of the Board and Chief Executive Officer. Additionally, the board consists of several independent directors: Mr. James Huang, Mr. Franklin Salisbury, Dr. Rajesh Shrotriya, Dr. Y. Alexander Wu, and Mr. Quan Zhou. <BR><BR>In summary, as of March 2022, the key members of the management team at CASI Pharmaceuticals, Inc. are Dr. Wei-Wu He and a group of independent directors including Mr. James Huang, Mr. Franklin Salisbury, Dr. Rajesh Shrotriya, Dr. Y. Alexander Wu, and Mr. Quan Zhou.

Is CASI Pharmaceuticals, Inc. overvalued or undervalued?

CASI Pharmaceuticals, Inc. is currently considered overvalued and rated as risky due to negative financial metrics, including a Price to Book Value of -3.67 and a year-to-date return of -56.54%, significantly underperforming the S&P 500.

As of 12 November 2019, the valuation grade for CASI Pharmaceuticals, Inc. moved from does not qualify to risky. The company is currently assessed as overvalued given its negative financial metrics and performance indicators. Key ratios include a Price to Book Value of -3.67, an EV to EBIT of -0.88, and an EV to Sales of 1.13, which highlight significant financial distress.<BR><BR>In comparison to peers, CASI Pharmaceuticals has a P/E ratio of -0.5556, while Assembly Biosciences, Inc. also rated as risky, has a P/E of -3.2679. Additionally, Fortress Biotech, Inc. has a P/E of -0.5040, indicating that CASI is not alone in its struggles but still reflects a concerning valuation relative to its industry. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -56.54% compared to the S&P 500's 2.44%, reinforcing the view that CASI Pharmaceuticals is overvalued.

Is CASI Pharmaceuticals, Inc. technically bullish or bearish?

As of August 4, 2025, CASI Pharmaceuticals, Inc. shows a mildly bearish technical trend, with mixed indicators suggesting underperformance compared to the S&P 500, including a 1-year return of -73.67%.

As of 4 August 2025, the technical trend for CASI Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are bearish, and the Bollinger Bands show a sideways trend on the weekly chart but bearish on the monthly. The KST is bullish weekly but bearish monthly, and the Dow Theory is mildly bearish on the weekly timeframe. The OBV is also mildly bearish on the weekly.<BR><BR>In terms of performance, CASI has significantly underperformed compared to the S&P 500 across all periods, with a 1-year return of -73.67% versus the S&P 500's 17.14%, and a 5-year return of -89.01% compared to the S&P 500's 96.61%. Overall, the current technical stance is mildly bearish, driven primarily by the bearish daily moving averages and mixed signals from other indicators.